• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy & clinical immunology international: official organ of the International Association of Allergology and Clinical Immunology >Sublingual Immunotherapy by Means of Disposable Single-Dose Containers: Tolerability and Acceptance in Patients with Allergic Rhinoconjunctivitis Due to Grass Pollen
【24h】

Sublingual Immunotherapy by Means of Disposable Single-Dose Containers: Tolerability and Acceptance in Patients with Allergic Rhinoconjunctivitis Due to Grass Pollen

机译：通过一次性单剂量容器进行舌下免疫治疗：因花粉致敏性鼻结膜炎患者的耐受性和接受性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Sublingual immunotherapy (SLIT) is appropriate for home treatment of allergic rhinoconjunctivitis and allergic bronchial asthma. This study investigated patient acceptance and tolerability of a new SLIT treatment. Methods/Data base: This observational cohort study included 177 patients with allergic rhinoconjunctivitis and/or allergic bronchial asthma. Patients self-administered SLIT drops during an initial updosing and treatment phase, and an optional maintenance treatment phase. Patient acceptance and tolerability of SLIT were recorded through physician assessment and patients' diaries after each phase. Data are presented using summary statistics. Statistical estimates (chi~2 and U test) examined differences between age groups (<= 14 and >= 15 years). Results: 90.2% of patients completed the initial updosing and treatment phase; median treatment duration was 154 days. Adverse drug reactions were recorded in 14 patients, only 1 event was serious. Over 90% of patients and physicians rated the tolerability of SLIT as good or very good both in the initial phase and the maintenance phase. Patients' acceptance of SLIT treatment was high: Handling and once-daily dosing was particularly acceptable in the initial phase (50.9% and 47.9% of patients, respectively, rated their satisfaction as very good). The percentage of patients responding to different eye and nose symptoms ranged from 69.6% to 80.9%. The proportion of patients receiving any symptomatically effective medication decreased from 93.8% to 59.4% in patients aged <= 14 years, and from 91.2% to 61.4% in patients aged >= 15 years. Conclusions: This observational study reported a high level of patient acceptance and tolerability with SLIT treatment in a predominantly young population.
机译：背景：舌下免疫疗法（SLIT）适用于过敏性鼻结膜炎和过敏性支气管哮喘的家庭治疗。这项研究调查了患者对新SLIT治疗的接受程度和耐受性。方法/数据库：该观察性队列研究包括177例过敏性鼻结膜炎和/或过敏性支气管哮喘患者。患者的自我给药SLIT在初始给药和治疗阶段以及可选的维持治疗阶段都会下降。在每个阶段后通过医师评估和患者日记记录SLIT的患者接受度和耐受性。数据使用汇总统计数据表示。统计估计（chi〜2和U检验）检验了年龄组（<= 14岁和> = 15岁）之间的差异。结果：90.2％的患者完成了初始用药和治疗阶段;中位治疗时间为154天。 14例患者发生药物不良反应，仅1例严重。在初始阶段和维护阶段，超过90％的患者和医生将SLIT的耐受性评为好或很好。患者对SLIT治疗的接受程度很高：在初始阶段，操作和每日一次给药特别令人接受（分别对50.9％和47.9％的患者表示非常满意）。对不同的眼睛和鼻子症状做出反应的患者百分比范围为69.6％至80.9％。年龄小于等于14岁的患者接受任何对症有效药物的比例从93.8％降至59.4％，年龄大于等于15岁的患者从91.2％降至61.4％。结论：这项观察性研究报道，在以年轻为主的人群中，SLIT治疗对患者的接受程度和耐受性较高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号